Magnetic Resonance Imaging (MRI) is the preferred method for visualizing soft tissues of the brain, but diagnosis is often based on subjective assessment. Now, a next-generation imaging solution with isotropic 3D resolution is poised to revolutionize the field of medical imaging by introducing a myriad of innovative applications within its post-processing solution.

SyntheticMR’s (Linköping, Sweden) new 3D release, SyMRI 3D, enables precise volumetric estimations of brain regions, a technique commonly referred to as parcellation, which empowers clinicians to gain deeper insights into brain structure and function. Furthermore, the exceptional resolution provided by SyMRI 3D facilitates comprehensive lesion analysis, ensuring a more accurate and in-depth assessment of medical conditions. The advanced SyMRI sequence introduces 3D resolution to quantitative values and tissue segmentations, ensuring the same level of precision in quantification as achieved with SyMRI's 2D imaging. SyMRI 3D has obtained approval in the EU and is now CE-Marked with preparations in place for its commercial launch at the start of 2024.

"We are delighted to see our 3D solution CE-marked and available on the European market," said Ulrik Harrysson, CEO at SyntheticMR AB. "SyMRI 3D represents the next generation of quantitative MRI, offering unprecedented resolution and accuracy in brain imaging, revolutionizing the landscape of medical diagnostics."

"This advanced sequence extends 3D resolution to quantitative values and tissue segmentations, matching the precision achieved in SyMRI's 2D imaging. The CE-marking for SyMRI 3D paves the way for physicians to make more informed decisions through quantitative imaging," added Kyle Frye, CCO & President of SyntheticMR Inc. "Receiving approval for SyMRI 3D will allow us to enable physicians to make better, more informed decisions using quantitative imaging." 

http://www.gzjiayumed.com/en/index.asp